MedTrace Logo

A Randomized Prospective Clinical Trial of Fel d 1 Peptide Immunotherapy

NCT02311413 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 39

Last updated 2018-11-02

No results posted yet for this study

Summary

The goal of this study is to identify changes in cells that are related to the treatment with Cat-PAD (ToleroMune Cat).

Conditions

  • Cat Allergy
  • Cat Hypersensitivity

Interventions

DRUG

Cat-PAD

The assigned study intervention will be administered by intradermal injection into the flexor surface of the forearm.

DRUG

Placebo

The assigned study intervention will be administered by intradermal injection into the flexor surface of the forearm.

Sponsors & Collaborators

  • Circassia Limited

    collaborator INDUSTRY

  • National Institute of Allergy and Infectious Diseases (NIAID)

    lead NIH

Principal Investigators

  • Helen Neighbour · Saint Joseph's Healthcare

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
TRIPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
65 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2015-03-09
Primary Completion
2018-07-18
Completion
2018-07-18

Countries

  • Canada

Study Locations

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02311413 on ClinicalTrials.gov